0EE0 fundamentals
Key facts
Market capitalization661.36 MUSD
Basic EPS (TTM)−4.93USD
Founded2012
CEOMatthew C. Kapusta
Websiteuniqure.com
About
uniQure NV engages in the discovery, development, and commercialization of innovative gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, Netherlands.
Valuation
Fundamental metrics to determine fair value of the stock
Growth and Profitability
Company’s recent performance and margins
−2,100.0%
−1,700.0%
−1,300.0%
−900.0%
−500.0%
Q4 '23
Q1 '24
Q2 '24
Q3 '24
Q4 '24
−75.00 M
−50.00 M
−25.00 M
0.00
25.00 M
Revenue
Net income
Net margin %
Revenue breakdown
Revenue streams and regions a business earns money from
Estimates
Revenue and Earnings forecasts and estimates accuracy
Dividends
Dividend yield, history and sustainability
0EE0 does not pay dividends
The company has not previously paid dividends and at the moment there is no information about whether it is going to pay them in the future
Financial health
Financial position and solvency of the company